NCT05503693View on ClinicalTrials.gov

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

62

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions

Healthy Subjects

Interventions

DRUG

AP303 50 μg

AP303 tablet

DRUG

AP303 150 μg

AP303 tablet

DRUG

AP303 300 μg

AP303 tablet

DRUG

AP303 600 μg

AP303 tablet

DRUG

Placebo 50 μg

Placebo tablet

DRUG

Placebo 150 μg

Placebo tablet

DRUG

Placebo 300 μg

Placebo tablet

DRUG

Placebo 600 μg

Placebo tablet

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors

lead

Alebund Pty Ltd

INDUSTRY